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Objective: The prognostic value of postoperative parameters reflecting the inflammatory
and nutritional status of patients undergoing cancer surgery has been rarely studied. This
study investigated the prognostic value of inflammatory and nutritional parameters
measured preoperatively and 1 month after curative gastrectomy for gastric cancer.
Methods: Data from a prospectively maintained database of 1,194 patients with gastric
cancer who underwent curative surgery in 2009–2018 were retrospectively reviewed.
Demographics, clinicopathologic characteristics, operative data, survival data, and
laboratory parameters were extracted. Neutrophil counts, lymphocyte counts, and
albumin levels before surgery and 1 month postoperatively were analyzed.
Results: In multivariable analysis adjusted for age, sex, and pathologic stage, high
neutrophil count (hazard ratio [HR] 1.09, 95% confidence interval [CI] 1.01–1.17, p =
0.022) and low albumin (HR 0.45, 95% CI 0.27–0.74, p = 0.002) 1 month postoperatively
were independent prognostic factors for overall survival. High neutrophil count (HR 1.09,
95% CI 1.02–1.16, p = 0.015) 1 month postoperatively was also an independent
prognostic factor for recurrence-free survival after adjusting for age, sex, body mass
index, extent of gastrectomy, and pathologic stage. Patients were classified into risk
groups based on thresholds of 4.2 × 103 cells/mm3 and 4.1 g/dl for 1-month neutrophil
count and albumin. High-risk groups had a significantly worse prognosis than low-risk
groups for overall survival (HR 5.87, 95% CI 3.28–10.51, p <0.001) and recurrence-free
survival (HR 1.52, 95% CI 1.07–2.16, p = 0.021).
Conclusions: Neutrophil count and albumin level 1 month after curative surgery reflect
long-term prognosis better than preoperative values. These parameters can be used to
stratify patients with the same stage into different prognostic groups.
Keywords: stomach neoplasms, inflammation, neutrophils, albumin, prognosis, survivalMarch 2021 | Volume 11 | Article 6339241
Guner et al. Prognostic Value of Postoperative Neutrophil and AlbuminGastric cancer is one of the common cancer types worldwide.
Although surgical treatment is known as the only curative
treatment option, a better survival has been achieved with
developing neoadjuvant and adjuvant treatment modalities.
Treatment decision-making for patients with gastric cancer is
determined primarily by TNM staging. Increasing evidence has
shown that inflammatory and nutritional status also influence
long-term outcomes. However, assessing this status is usually
conducted in the preoperative period. It is hypothesized that
laboratory values obtained after curative treatment may reflect
the prognosis better than the preoperative values. In the present
study, we evaluated the associations between laboratory values
obtained 1 month after curative surgery and survival. Our results
showed that 1-month neutrophil and albumin values were
independent prognostic factor of overall survival and 1-month
neutrophil count was an independent prognostic factor of
recurrence-free survival. Risk stratification according to these
laboratory parameters revealed worse overall and recurrence-free
survival in high-risk groups than in low-risk groups.INTRODUCTION
Gastric cancer is one of the most common solid organ
malignancies worldwide, and radical surgery remains the only
potentially curative treatment. Risk stratification based on
prognostic factors is essential for predicting long-term
outcomes and determining the need for adjuvant therapy (1).
TNM staging is the standard method of prognosis prediction;
however, parameters reflecting inflammatory status may also have a
role in prognosis prediction. Preoperative neutrophil count,
neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte
ratio (PLR), systemic immune-inflammation index (SII),
prognostic nutritional index (PNI), and albumin level have all
been associated with survival (2–7). We previously demonstrated
that among many complex parameters, the simple parameter of a
high preoperative neutrophil count is a useful prognostic marker for
poor overall survival (OS) and recurrence-free survival (RFS) (7, 8).
While a number of gastric cancer studies focused on
preoperative status, few studies explored the implications of
postoperative parameters (3–5). Patients are often reassessed 1
month after gastrectomy, prior to initiating adjuvant therapy. It is
assumed that nutritional defects and inflammation associated with
the disease and surgery would have been resolved by this time.
We hypothesized that parameters obtained 1 month after
curative surgery may reflect patient status and estimate long-
term outcomes. To explore this hypothesis, we investigated the
prognostic value of inflammation and nutritional parameters
measured preoperatively and 1 month after curative gastrectomy
for gastric cancer.MATERIALS AND METHODS
From a prospectively maintained database, we retrospectively
reviewed the data of 1,932 consecutive patients with histologicallyFrontiers in Oncology | www.frontiersin.org 2confirmed gastric adenocarcinoma who underwent radical
gastrectomy at the Severance Hospital of Yonsei University
Health System (Seoul, Korea) between March 2009 and June
2018. The exclusion criteria for the study were as follows: (i)
non-curative surgery; (ii) metastatic disease; (iii) malignancy of
another organ; (iv) neoadjuvant treatment; (v) emergency surgery;
(vi) active infection or immunologic disease; (vii) major
postoperative complication (Clavien-Dindo classification Grade
3 or higher); or (viii) incomplete laboratory test data. This study
was approved by the Institutional Review Board of Severance
Hospital (4-2020-1084).
Clinicopathologic characteristics, including age, sex, body
mass index (BMI), medical comorbidities, American Society of
Anesthesiologists physical status score, pathologic stage, and
adjuvant treatment, were extracted from the database.
Perioperative data, including surgical approach, extent of
lymphadenectomy and gastrectomy, operation time,
intraoperative blood loss, and combined resection, were
likewise extracted. The extent of lymphadenectomy and
gastrectomy was performed in accordance with Korean and
Japanese guidelines (9, 10). The pathologic stage was
determined according to the 8th edition of the American Joint
Committee on Cancer staging system (11). Adjuvant
chemotherapy was recommended for patients with stage II or
higher disease.
Patients were followed according to a fixed schedule: 1 month
after gastrectomy, every 3 months for 2 years, and then every 6
months for 3 years thereafter. The follow-up schedule consisted
of clinical and laboratory examinations, imaging, and endoscopic
evaluation. The last database update was in April 2020.
Neutrophil counts, lymphocyte counts, and albumin levels
were obtained from the results of blood samples collected
within 1 week before surgery (preop); on the day of surgery
(D0); on postoperative days 1 (D1), 3 (D3), and 5 (D5); and 1
month after surgery (M1). Neutrophil, lymphocyte, and albumin
levels at one month after surgery was presented as neutrophil-
M1, lymphocyte -M1, and albumin -M1 respectively.
The study endpoints were OS and RFS. Survival times were
calculated from the date of surgery to the time of death for OS
and clinical, histologic, or radiologic recurrence for RFS. Data
from the remaining patients were censored at the last follow-up
evaluation. Deaths caused by cancer progression or cancer-
related long-term complications were defined as cancer-related
deaths, while deaths unrelated to the malignancy were defined as
non-cancer deaths. Recurrence pattern was defined as
peritoneum-associated or extra-peritoneal recurrence. Any
recurrence involving the peritoneum (peritoneum-only or
combined) was defined as a peritoneum-associated recurrence.
Any recurrence not involving the peritoneum (locoregional
recurrence including the anastomosis site or lymph nodes,
distant recurrence including hematogenous metastasis, and
metastasis at extra-abdominal lymph nodes) was defined as an
extra-peritoneal recurrence.
Statistical Analysis
Statistical analysis was performed using R software (R
Foundation for Statistical Computing, Vienna, Austria) withMarch 2021 | Volume 11 | Article 633924
Guner et al. Prognostic Value of Postoperative Neutrophil and Albuminthe required R packages. Data were presented as mean ±
standard deviation or median (1st–3rd quartiles) for
continuous variables, and as frequencies (percentages) for
categorical variables. The normality distribution of continuous
variables was assessed with the Shapiro–Wilk test and visual
inspection of normal Q–Q plots. Pearson correlation test was
used for the correlation between variables.
To evaluate the prognostic effects of laboratory values on
survival, we first analyzed clinicopathologic factors influencing
long-term prognosis. Cox proportional hazards regression models
were used, and the purposeful selection method described by
Hosmer and Lemeshow was applied to the factors (12). Briefly,
any variable with a p-value <0.25 on univariable testing and all
variables of known clinical importance were entered into the
multivariable model. Coefficient changes and interactions were
also assessed, and variables with a p-value <0.05 were considered
for the final model. The selected clinicopathologic factors were
used to test the prognostic effects of laboratory values in further
multivariable analysis. Schoenfeld residuals and the Grambsch–
Therneau test were used to test the proportional hazards
assumption. Martingale residuals and penalized spline fit were
used to evaluate the linearity assumption. All continuous variables
were assessed for definitive evidence of non-linear relationships
using penalized smoothing splines (pspline function from the R
Survival Package), and linear variables were used in the Cox
regression models without grouping by cut-off value.
Univariable (only laboratory values) and multivariable analysis
with backward selection based on the Akaike’s information
criterion (clinicopathologic factors and all laboratory values)
were used in the regression models. The results were described
as hazard ratios (HRs) with 95% confidence intervals (CIs).
Survival outcomes were analyzed using Kaplan–Meier curve
analysis, and comparisons between groups were performed using
the log-rank test. Various cut-offs were analyzed, and thresholds
were selected based on the highest log-rank score and lowest p-
value. P-values were two-sided and statistical significance was
defined as a p-value <0.05 unless otherwise stated.RESULTS
Of the 1,194 patients with gastric cancer enrolled in the study, 751
(62.9%) were male and 443 (37.1%) were female (Table 1). The
median age was 60 (51–68) years. There were 801 (67.1%) patients
with stage I cancer, 171 (14.3%) patients with stage II cancer, and
222 (18.6%) patients with stage III cancer. A total of 355 (29.7%)
patients received adjuvant chemotherapy. The median follow-up
time for patients with no event was 39 (26–58) months.
Recurrence was detected in 127 (10.6%) patients, and 101
(8.5%) patients died. In patients with recurrence, 74 (58%) had
peritoneum-associated recurrence, while 53 (42%) experienced
extra-peritoneal recurrence. Among patients who died during the
follow-up period, 85 (84%) died from gastric cancer-related
causes, while 16 (16%) died from non-cancer causes.
Postoperative changes in laboratory values are presented in
Figure 1. Neutrophil counts increased on D0, then graduallyFrontiers in Oncology | www.frontiersin.org 3decreased and reached a median value of 3.3 × 103 cell/mm3
(2.5–4.5) at 1 month after surgery. Lymphocyte counts and
albumin levels decreased initially after surgery and then
returned to median values of 2 × 103 cell/mm3 (1.7–2.4) and
4.2 g/dl (4.0–4.5), respectively, at 1 month after surgery. The
correlation matrix and the correlation coefficients between the
variables were presented in Supplemental Figure 1.
Univariable and Multivariable Analyses for
Overall Survival and Recurrence-Free
Survival
In Cox regression analysis of clinicopathologic variables, age, sex,
and pathologic stage were identified as independent prognostic
factors for OS, and age, sex, BMI, extent of gastrectomy, andTABLE 1 | Clinicopathologic characteristics of all included patients.
Variable n (%) or median
(Q1–Q3) (N = 1194)
Age (y) 60 (51–68)
Sex Male 751 (62.9)
Female 443 (37.1)
Body mass index (kg/m2) 23.6 (21.5–25.9)




Comorbidity No 542 (45.4)
Yes 652 (54.6)
Previous abdominal surgery No 722 (60.5)
Yes 472 (39.5)
CEA (ng/ml) 1.8 (1.1–2.7)
CA 19-9 (U/ml) 7.9 (4.5–13.7)
Neutrophil count (× 103 cell/mm3) 3.6 (2.8–4.5)
Lymphocyte count (× 103 cell/mm3) 2.0 (1.6–2.4)
Albumin (g/dl) 4.4 (4.2–4.7)
NLR 1.8 (1.3–2.4)
PNI 54.9 (51.2–58.3)
Approach Open 212 (17.8)
Laparoscopy 558 (46.7)
Robotic 424 (35.5)
Extent of lymphadenectomy D1+ 752 (63.0)
D2 442 (37.0)
Extent of gastrectomy Subtotal 962 (80.6)
Total 232 (19.4)
Operation time (min) 160.0 (130.0–200.0)
Intraoperative blood loss (ml) 41.0 (20.0–90.0)
Combined resection No 1057 (88.5)
Yes 137 (11.5)
Transfusion No 1169 (97.9)
Yes 25 (2.1)








Pathologic stage I 801 (67.1)
II 171 (14.3)
III 222 (18.6)March 2021 | VolumeASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; NLR, neutrophil/
lymphocyte ratio; PNI, Prognostic Nutritional index; Q1–Q3, first quartile–third quartile.11 | Article 633924
Guner et al. Prognostic Value of Postoperative Neutrophil and Albuminpathologic stage were identified as independent prognostic
factors for RFS. These factors were adjusted for during
multivariable analysis of laboratory variables (pre- and
postoperative neutrophil counts, lymphocyte counts, and
albumin levels). Most of these laboratory values were
statistically significant prognostic factors in univariable analysisFrontiers in Oncology | www.frontiersin.org 4(Table 2). In adjusted multivariable analysis, both neutrophil-
M1 (HR 1.09, 95% CI 1.01–1.17, p = 0.022) and albumin-M1
(HR 0.45, 95% CI 0.27–0.74, p = 0.002) were independent
prognostic factors for OS. Only neutrophil-M1 was an
independent prognostic factor for RFS (HR 1.09, 95% CI 1.02–
1.16, p = 0.015).FIGURE 1 | Box plots of neutrophil count, lymphocyte count, and albumin level at different time points. Y-axis represents × 103 cells/ml for neutrophils and
lymphocytes and g/dl for albumin. (D, day; M, month; preop, preoperative).TABLE 2 | Univariable and multivariable analyses for overall and recurrence-free survival.
Overall survival Recurrence-free survival
Univariable HR Adjusted HR† Univariable HR Adjusted HR††
Neutrophil preop 1.16 (1.05–1.28) (p = 0.002) 1.14 (1.03–1.25) (p = 0.008)
Neutrophil-M1 1.09 (1.03–1.16) (p = 0.002) 1.09 (1.01–1.17) (p = 0.022) 1.06 (1.00–1.13) (p = 0.071) 1.09 (1.02–1.16) (p = 0.015)
Lymphocyte preop 0.52 (0.37–0.72) (p <0.001) 0.65 (0.49–0.87) (p = 0.003)
Lymphocyte-M1 0.59 (0.41–0.84) (p = 0.004) 0.79 (0.58–1.07) (p = 0.126)
Albumin preop 0.24 (0.17–0.34) (p <0.001) 0.34 (0.24–0.47) (p <0.001)
Albumin-M1 0.25 (0.18–0.36) (p <0.001) 0.45 (0.27–0.74) (p = 0.002) 0.37 (0.27–0.52) (p <0.001)March 2021 |†Age, sex, and pathologic stage were added to the model.
††Age, sex, body mass index, extent of gastrectomy, and pathologic stage were added to the model.
CI, confidence interval; HR, hazard ratio; M1, 1 month after surgery; preop, preoperative.
Hazard Ratios were presented as HR (95% Confidence Intervals, p value).Volume 11 | Article 633924
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month absolute values of independent prognostic parameters
and HRs are shown in Figure 2. Adjusted spline curves showed
that HRs for OS increased as neutrophil-M1 increased and
decreased as albumin-M1 increased. HRs for RFS were
positively correlated with neutrophil-M1. The overall
relationships showed a linear pattern. Conversely, changes
from preoperative to 1-month reassessment values (deltas) and
HRs exhibited non-linear relationships (Supplemental Figure 2);
we therefore did not include deltas in further analyses.Threshold Selection for Survival
Comparisons
We investigated the optimal cut-off values using the maximum
log-rank score method and found that a neutrophil-M1 of 4.22 ×
103 cell/mm3 was the optimal threshold for OS and a neutrophil-
M1 of 4.17 × 103 cell/mm3 was the optimal threshold for RFS
(Supplemental Figure 3A). For albumin-M1, 4.1 g/dl was the
optimal threshold value for OS (Supplemental Figure 3B). For
the simplicity of clinical application, 4.2 × 103 cell/mm3 and 4.1
g/dl were selected as the thresholds for neutrophil count and
albumin level and used to dichotomize patients into groups.Comparisons of Overall Survival
Survival curves were compared for all patients (Figures 3A, B),
stage I patients (Figures 3C, D), and stage II/III patients
(Figures 3E, F). In all patients, high neutrophil-M1 (HR 2.04,
95% CI 1.38–3.02, p <0.001; Figure 3A) and low albumin-M1
(HR 0.26, 95% CI 0.16–0.41, p <0.001; Figure 3B) were
significantly associated with poorer OS. In stage I patients, low
albumin-M1 was significantly associated with poorer OS (HR
0.19, 95% CI 0.06–0.59, p = 0.004; Figure 3D) but high
neutrophil-M1 was not (HR 2.45, 95% CI 0.94–6.35, p = 0.066;
Figure 3C). For patients with stage II/III cancer, high
neutrophil-M1 (HR 2.13, 95% CI 1.38–3.27, p = 0.001; Figure
3E) and low albumin-M1 (HR 0.49, 95% CI 0.30–0.81, p = 0.005;
Figure 3F) were both associated with significantly worse OS.
In stage II/III patients, 1-, 3- and 5-year OS rates were 91.9,
71.7, and 63.5%, respectively, for the high neutrophil-M1 group.
By contrast, these rates were 96.2, 86.3, and 78.9% for the low
neutrophil-M1 group. Similarly, 1-, 3- and 5-year OS rates were
93.5, 77.6, and 69.1% for the low albumin-M1 group and 96.7,
87.8, and 81.5% for the high albumin-M1 group.Overall Survival According to Combined
Neutrophil-M1 and Albumin-M1 Values
Neutrophil counts and albumin levels 1 month after surgery were
combined for further OS risk stratification. The risk categories
were high-risk (high neutrophils and low albumin), moderate-
risk (either high neutrophils or low albumin), and low-risk (low
neutrophils and high albumin). Compared with the low-riskFrontiers in Oncology | www.frontiersin.org 5group, the moderate-risk group (HR 3.16, 95% CI 1.79–45.58,
p <0.001) and high-risk group (HR 5.87, 95% CI 3.28–10.51,A
B
C
FIGURE 2 | Spline curves for associations between HRs and 1-month
absolute values for neutrophil count (A), lymphocyte count (B), and albumin
level (C). The blue curves represent penalized smoothing splines for adjusted
HRs. Blue-shaded areas represent 95% confidence intervals. HRs were
estimated using Cox proportional hazards models adjusted for age, sex,
pathologic stage for OS and adjusted for age, sex, pathologic stage, body
mass index, and extent of gastrectomy for RFS. Light gray areas just above
the x-axis represent density plots. Vertical dotted lines indicate the first
quartile, median, and third quartile values. (HR, hazard ratio; M1, 1 month;
OS, overall survival; RFS, recurrence-free survival).March 2021 | Volume 11 | Article 633924
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patients (Figure 4A). The 5-year OS rates of the low-,
moderate-, and high-risk groups were 94.8, 87.0, and
76.7%, respectively.
In stage I patients, only the high-risk group had significantly
poorer OS than the low-risk group (HR 7.39, 95% CI 1.95–28.01,
p = 0.003; Figure 4B). In stage II/III patients, OS was
significantly worse for both the moderate-risk group (HR 2.20,
95% CI 1.18–4.11, p = 0.014) and high-risk group (HR 3.64, 95%
CI 1.90–6.96, p <0.001), compared with the low-risk group
(Figure 4C). The 5-year OS rates in stage II/III patients wereFrontiers in Oncology | www.frontiersin.org 684.3, 73.9, and 60.4% for the low-, moderate, and high-risk
groups, respectively.
Comparisons of Recurrence-Free Survival
The high neutrophil-M1 group had significantly poorer RFS (HR
1.52, 95% CI 1.07–2.16, p = 0.021) when considering all patients
(Figure 5A). The 1-, 3-, and 5-year RFS rates were 92.4, 87, and
83.4%, respectively, for the high neutrophil-M1 group and 96.2,
90.5, and 89.0% for the low neutrophil-M1 group. RFS did not
differ between high and low neutrophil-M1 groups in stage I




FIGURE 3 | Overall survival curves of patients grouped according to low or high 1-month neutrophil and albumin values. (A) all patients, neutrophil count; (B) all
patients, albumin level; (C) stage I patients, neutrophil count; (D) stage I patients, albumin level; (E) stage II/III patients, neutrophil count; (F) stage II/III patients,
albumin level. (ALB, albumin; HR, hazard ratio; NTR, neutrophil; OS, overall survival).March 2021 | Volume 11 | Article 633924
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M1 group in stage II/III patients (HR 1.58, 95% CI 1.09–2.30, p =
0.017; Figure 5C). In stage II/III patients, the 1-, 3-, and 5-year
RFS rates were 76.1, 64.4, and 59.5%, respectively, for the high




FIGURE 4 | Overall survival curves for low-, moderate-, and high-risk groups
based on the combination of 1-month neutrophil and albumin values. (A) all
patients, (B) stage I patients, (C) stage II/III patients. (HR, hazard ratio; OS,
overall survival).Frontiers in Oncology | www.frontiersin.org 7A
B
C
FIGURE 5 | Recurrence-free survival curves of patients grouped according
to low or high 1-month neutrophil count. (A) all patients, (B) stage I patients,
(C) stage II/III patients. (HR, hazard ratio; NTR, neutrophil; RFS, recurrence-
free survival).March 2021 | Volume 11 | Article 633924
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The key finding of this study was that specific inflammatory and
nutritional parameters measured 1 month after curative surgery
for gastric cancer were prognostic factors of long-term outcomes
and appeared to be more useful than preoperative values. In
univariable analysis, several preoperative and postoperative
values were significantly associated with long-term prognosis.
However, in multivariable analysis adjusted for clinical
parameters, 1-month postoperative neutrophil count and
albumin level were identified as independent prognostic factors
of OS, and 1-month postoperative neutrophil count was also
independent prognostic factors of RFS. When we divided
patients into different risk groups using threshold values,
combining neutrophil count and albumin level increased their
prognostic ability for OS. Patients in the high-risk group (high
neutrophil count and low albumin level) had poorer OS. For
recurrence-free survival (RFS), patients in the high-risk group
based on a high neutrophil count showed higher recurrence rate.
Although the prognostic ability of these parameters was
demonstrated when considering all patients included in the
study, their prognostic value was particularly obvious in
patients with stage II/III cancer.
One of the most important findings of this study is the
relationship between the neutrophil count measured 1 month
after surgery and both OS and RFS. There is little previous
evidence regarding the prognostic value of neutrophil counts, as
most studies have not evaluated neutrophil count as a single
independent factor. Its prognostic value has primarily been
evaluated using neutrophil-containing parameters, such as
NLR, SII, or neutrophil–albumin ratio (NAR) (3, 13, 14). Our
previous study demonstrated that preoperative neutrophil count
was a strong independent prognostic factor for OS and RFS after
adjusting for clinical and pathologic characteristics. In the
present study, which contained a larger number of patients
and extensive updates regarding chemotherapy and survival
details, we found that postoperative neutrophil counts may be
more useful than preoperative counts. The association between
postoperative neutrophil count and both OS and RFS may be
explained by several possible mechanisms. Various neutrophil-
related elements (such as tumor-associated neutrophils, vascular
endothelial growth factor, and neutrophil extracellular traps)
may promote mutations leading to tumorigenesis and tumor cell
proliferation, contribute to tumor-related angiogenesis, induce
cancer cells to metastasize, inhibit T-cell activity against tumor
cells, and increase adhesion between circulating tumor cells and
organs (15–19). All of these mechanisms suggest that high
neutrophil counts may lead to a poorer prognosis. Conversely,
it is possible that elevated neutrophil counts are simply the result
of ongoing tumor-associated inflammation and do not directly
contribute to a worse prognosis.
Albumin measured 1 month after surgery was also identified
as a prognostic indicator for OS. Albumin is well-established
marker of nutritional status. With increasing evidence of the
relationship between hypoalbuminemia and poor prognosis, the
prognostic value of a low albumin level has been tested and
validated in several composite ratios or cumulative scores for aFrontiers in Oncology | www.frontiersin.org 8variety of malignancies (20–22). In this study, we defined three
risk groups based on neutrophil count and albumin values to
assess the clinical applicability of our findings. Using this
stratification system, which was similar to the categorization
strategy used for the albumin-neutrophil combined prognostic
grade in patients with lung cancer (23), we observed a
significantly worse prognosis in the high-risk group than in the
low-risk group. In our cohort, 5-year OS rate was 94.8% for the
low-risk group but only 76.7% for the high-risk group. This
survival difference between risk groups was most apparent in
patients with stage II/III cancer: 84.3% for the low-risk group and
60.4% for the high-risk group.
The literature exploring the prognostic value of postoperative
reassessments is limited. For patients with gastric cancer, low
PNI in the postoperative period has been associated with worse
survival, regardless of preoperative values (4, 5). This finding is
consistent with our results. In a study evaluating NLR before and
after surgery, high NLR values in both periods were associated
with poorer survival (3). Although dynamic changes such as
delta values between preoperative and postoperative values have
been evaluated for various organ cancers, postoperative absolute
values have been most commonly evaluated for colorectal cancer,
hepatocellular carcinoma, and pancreatic carcinoma (24–28).
Most previous research examined NLR and PNI, although
postoperative changes for PLR and SII have also been
evaluated; all of these parameters were associated with
prognosis (29, 30). However, these parameters were complex
scores combining two or more parameters. By contrast, we have
focused primarily on simple parameters, such as neutrophil
count, lymphocyte count, and albumin level. As noted in our
previous study, simple parameters were found to adequately
reflect inflammatory status. We also evaluated various complex
parameters, including NLR, PLR, and PNI, but they were not
superior to the simple parameters (data not shown).
We used absolute values in our analysis instead of delta values
primarily because non-linear relationships were observed
between delta values and HRs. Non-linear relationships would
lead to inaccuracies if delta values were categorized as decreased
or increased by dichotomizing the values using single cut-off
values. To overcome this problem, patients could be divided into
multiple subgroups based on delta values; however, multiple
subgroups would make risk assessment more complicated and
less useful for clinical practice. In the present study, we used only
thresholds for absolute values with linear HR relationships. The
relevant thresholds used in this study were calculated statistically
and assessed clinically. These thresholds require validation in
further clinical studies.
One month after curative surgery can be considered an ideal
time for reassessment. It is late enough for the inflammatory
response to surgical intervention to resolve and early enough to
allow appropriate decision making before initiating adjuvant
therapy. In the present study, we excluded patients with major
perioperative complications to avoid potential bias associated
with inflammation secondary to these complications. Previous
studies of patients with gastric cancer have evaluated 3- or 6-
month postoperative values as potential prognostic factors;
however, the interpretation of the results at these times may beMarch 2021 | Volume 11 | Article 633924
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of adjuvant chemotherapy (4, 5, 26, 30).
Despite robust methodology and use of a comprehensive
database, the present study had some limitations. First, all
patients underwent surgery in a single tertiary center, and all
operations were performed by the same surgeon. Experience bias
may limit the generalizability of our findings. Second, because of
the retrospective study design, it was not possible to use immune
parameters as a diagnostic tool during long-term follow-up.
However, by demonstrating the link between survival and
post-treatment laboratory values, our results may form the
basis for future investigations of the relationship between
recurrence and laboratory values. Third, although all patients
were treated according to current guidelines, adjuvant treatment
may have varied and impacted the outcomes.
In conclusion, reassessment of a patient’s inflammatory and
nutritional status 1 month after curative surgery may provide
important information regarding long-term prognosis and may be
more useful than preoperative values. These parameters can be used
to stratify patients within the same pathologic stage into different
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Supplemental Figure 1 | Correlation matrix among the preoperative and 1-
month neutrophil count, lymphocyte count and albumin values. Positive correlations
are displayed in blue and negative correlations in red color. Color intensity and the
circle size are proportional to the correlation coefficients. Numbers also show the
correlation coefficients between parameters. (preop, preoperative, M1, 1 month).
Supplemental Figure 2 | Spline curves for associations between HRs and delta
values (1-month minus preoperative) for neutrophil count (A), lymphocyte count (B),
and albumin level (C). The blue curves represent penalized smoothing splines for
adjusted HRs. Blue-shaded areas represent 95% confidence intervals. HRs were
estimated using Cox proportional hazards models adjusted for age, sex, and
pathologic stage for OS and adjusted for age, sex, pathologic stage, body mass
index, and extent of gastrectomy for RFS. Light gray areas just above the x-axis
represent density plots. Vertical dotted lines indicate the first quartile, median, and
third quartile values. (HR, hazard ratio; M1, 1 month; OS, overall survival; RFS,
recurrence-free survival).
Supplemental Figure 3 | Various cut-off values of neutrophil count (A) and
albumin level (B) and their associated log-rank test scores for survival. (OS, overall
survival; RFS, recurrence-free survival).REFERENCES
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